Chemical formula: C₂₆H₂₆F₂N₂ Molecular mass: 404.495 g/mol PubChem compound: 941361
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07CA03 | Flunarizine | N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SIBELIUM Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Flunarizine is an active ingredient of these brands:
Austria (AT)
Brazil (BR)
Ecuador (EC)
France (FR)
Germany (DE)
Hong Kong (HK)Ireland (IE)
Malta (MT)
Mexico (MX)
Netherlands (NL)
Romania (RO)
Singapore (SG)
South Africa (ZA)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
